CB1 Receptor
Cannabinoid receptor type 1. A G protein-coupled receptor (GPCR) primarily expressed in the central nervous system. The primary target of THC's psychoactive effects.
In Depth
CB1 receptors are among the most abundant GPCRs in the brain, concentrated in the basal ganglia, cerebellum, hippocampus, prefrontal cortex, and amygdala. They are coupled to Gi/o proteins, inhibiting adenylyl cyclase and modulating ion channels. CB1 activation reduces presynaptic neurotransmitter release, making the ECS a key regulator of synaptic tone. CB1 receptors are also expressed peripherally in adipose tissue, liver, and the GI tract.
Related Terms
Further Reading
More in Pharmacology
Endocannabinoid System (ECS)
A lipid-based retrograde neurotransmitter system comprising endogenous cannabinoids (endocannabinoids), their receptors (CB1, CB2), and metabolic enzymes.
CB2 Receptor
Cannabinoid receptor type 2. A GPCR primarily expressed in immune tissues and peripheral organs. Less abundant in the CNS than CB1.
Anandamide (AEA)
N-arachidonoylethanolamine. The first endocannabinoid identified. A partial agonist at CB1 and CB2 receptors, named from the Sanskrit word "ananda" meaning bliss.
2-Arachidonoylglycerol (2-AG)
The most abundant endocannabinoid in the brain. A full agonist at both CB1 and CB2 receptors.
FAAH (Fatty Acid Amide Hydrolase)
The primary enzyme responsible for degrading anandamide and other fatty acid amides. A key target for increasing endocannabinoid tone.